CN113993842B - 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途 - Google Patents

琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途 Download PDF

Info

Publication number
CN113993842B
CN113993842B CN202080043350.XA CN202080043350A CN113993842B CN 113993842 B CN113993842 B CN 113993842B CN 202080043350 A CN202080043350 A CN 202080043350A CN 113993842 B CN113993842 B CN 113993842B
Authority
CN
China
Prior art keywords
compound
isolated compound
mitochondrial
complex
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080043350.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113993842A (zh
Inventor
芒努斯·约阿基姆·汉松
阿尔瓦尔·格伦贝格
马茨·埃斯基尔·埃尔默
马克·理查德·法梅里
史蒂文·詹姆斯·莫斯
李·罗伯特·韦伯斯特
马修·艾伦·格雷戈里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aiboliwa Co ltd
Original Assignee
Aiboliwa Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aiboliwa Co ltd filed Critical Aiboliwa Co ltd
Publication of CN113993842A publication Critical patent/CN113993842A/zh
Application granted granted Critical
Publication of CN113993842B publication Critical patent/CN113993842B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202080043350.XA 2019-06-19 2020-06-18 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途 Active CN113993842B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
DKPA201970384 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Publications (2)

Publication Number Publication Date
CN113993842A CN113993842A (zh) 2022-01-28
CN113993842B true CN113993842B (zh) 2024-07-16

Family

ID=71130953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080043350.XA Active CN113993842B (zh) 2019-06-19 2020-06-18 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途

Country Status (10)

Country Link
US (2) US11565998B2 (enExample)
EP (2) EP3986862B1 (enExample)
JP (2) JP7699551B2 (enExample)
KR (1) KR102871719B1 (enExample)
CN (1) CN113993842B (enExample)
CA (1) CA3143112A1 (enExample)
IL (1) IL288990B2 (enExample)
MA (1) MA56506A (enExample)
MX (1) MX2021015137A (enExample)
WO (1) WO2020254484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458957A (zh) * 2014-04-08 2017-02-22 纽维制药有限公司 新型细胞可渗透琥珀酸化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
CA2944575A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458957A (zh) * 2014-04-08 2017-02-22 纽维制药有限公司 新型细胞可渗透琥珀酸化合物

Also Published As

Publication number Publication date
MX2021015137A (es) 2022-01-18
US20230033294A1 (en) 2023-02-02
WO2020254484A1 (en) 2020-12-24
US20220162162A1 (en) 2022-05-26
EP4360708A2 (en) 2024-05-01
JP2025004155A (ja) 2025-01-14
EP3986862A1 (en) 2022-04-27
MA56506A (fr) 2022-04-27
CN113993842A (zh) 2022-01-28
KR102871719B1 (ko) 2025-10-15
IL288990A (en) 2022-02-01
EP3986862C0 (en) 2024-01-24
US11565998B2 (en) 2023-01-31
CA3143112A1 (en) 2020-12-24
US12162824B2 (en) 2024-12-10
JP7699551B2 (ja) 2025-06-27
JP2022538009A (ja) 2022-08-31
KR20220024780A (ko) 2022-03-03
IL288990B2 (en) 2025-09-01
BR112021024510A2 (pt) 2022-01-18
EP3986862B1 (en) 2024-01-24
IL288990B1 (en) 2025-05-01
AU2020298031A1 (en) 2022-02-03
EP4360708A3 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
US12257238B2 (en) Magnesium biotinate compositions and methods of use
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
EA016811B1 (ru) Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний
CN103833712B (zh) 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
CN113993842B (zh) 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途
US11999708B1 (en) Thiazole tethered organoselenides as 5-lipoxygenase inhibitors
AU2020298031B2 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
CN107405503A (zh) 鞣花酸二水合物在药物制剂中调节血糖水平的用途
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
US11504355B2 (en) Ergothioneine compositions and methods for maintaining and/or increasing vitamin C levels in cells and organisms
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
WO2017060418A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
JP2010500387A (ja) 結晶形態のエポチロンｂおよび医薬組成物における使用
HK40085297A (en) Impurity in plinabulin or preparation thereof, and use thereof
CN105530929B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在预防和治疗糖尿病中的用途
EP2638902B1 (en) Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
WO2021108923A1 (en) Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
CN114846019A (zh) 类固醇和开环甾类化合物的共晶体以及包含其的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant